- Coordinates
- PDB Format
- Method
- ELECTRON MICROSCOPY
- Oligo State
- hetero-3-3-3-mer
- Ligands
- 22 x NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- 3 x NAG- NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
NAG-NAG-NAG.23: 4 residues within 4Å:- Chain D: N.73, S.75, I.76, Y.80
No protein-ligand interaction detected (PLIP)NAG-NAG-NAG.24: 4 residues within 4Å:- Chain F: N.73, S.75, I.76, Y.80
No protein-ligand interaction detected (PLIP)NAG-NAG-NAG.25: 4 residues within 4Å:- Chain H: N.73, S.75, I.76, Y.80
No protein-ligand interaction detected (PLIP)- 27 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)(Non-functional Binders)
NAG.26: 2 residues within 4Å:- Chain A: Y.28, N.61
Ligand excluded by PLIPNAG.27: 3 residues within 4Å:- Chain A: N.122, T.124, V.127
Ligand excluded by PLIPNAG.28: 2 residues within 4Å:- Chain A: E.132, N.165
Ligand excluded by PLIPNAG.29: 2 residues within 4Å:- Chain A: G.232, N.234
Ligand excluded by PLIPNAG.30: 3 residues within 4Å:- Chain A: N.280, E.281, N.282
Ligand excluded by PLIPNAG.31: 2 residues within 4Å:- Chain A: N.603, T.604
Ligand excluded by PLIPNAG.32: 1 residues within 4Å:- Chain A: N.616
Ligand excluded by PLIPNAG.33: 1 residues within 4Å:- Chain A: N.657
Ligand excluded by PLIPNAG.34: 4 residues within 4Å:- Chain A: N.709, I.1130, G.1131
- Chain B: D.796
Ligand excluded by PLIPNAG.35: 1 residues within 4Å:- Chain B: N.61
Ligand excluded by PLIPNAG.36: 3 residues within 4Å:- Chain B: N.122, V.127, K.129
Ligand excluded by PLIPNAG.37: 1 residues within 4Å:- Chain B: N.165
Ligand excluded by PLIPNAG.38: 2 residues within 4Å:- Chain A: H.519
- Chain B: N.234
Ligand excluded by PLIPNAG.39: 3 residues within 4Å:- Chain A: K.558
- Chain B: E.281, N.282
Ligand excluded by PLIPNAG.40: 1 residues within 4Å:- Chain B: N.603
Ligand excluded by PLIPNAG.41: 1 residues within 4Å:- Chain B: N.616
Ligand excluded by PLIPNAG.42: 1 residues within 4Å:- Chain B: N.657
Ligand excluded by PLIPNAG.43: 5 residues within 4Å:- Chain B: A.706, E.1072, K.1073, N.1074
- Ligands: NAG.44
Ligand excluded by PLIPNAG.44: 1 residues within 4Å:- Ligands: NAG.43
Ligand excluded by PLIPNAG.45: 2 residues within 4Å:- Chain C: Y.28, N.61
Ligand excluded by PLIPNAG.46: 1 residues within 4Å:- Chain C: N.122
Ligand excluded by PLIPNAG.47: 3 residues within 4Å:- Chain B: R.357, Y.396
- Chain C: N.165
Ligand excluded by PLIPNAG.48: 1 residues within 4Å:- Chain C: N.234
Ligand excluded by PLIPNAG.49: 3 residues within 4Å:- Chain C: N.280, E.281, N.282
Ligand excluded by PLIPNAG.50: 1 residues within 4Å:- Chain C: N.603
Ligand excluded by PLIPNAG.51: 1 residues within 4Å:- Chain C: N.616
Ligand excluded by PLIPNAG.52: 1 residues within 4Å:- Chain C: N.657
Ligand excluded by PLIP- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Yan, R. et al., Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodies. Cell Res. (2021)
- Release Date
- 2021-03-10
- Peptides
- Spike glycoprotein: ABC
Immunoglobulin heavy variable 1-8,Immunoglobulin heavy variable 1-8,chain H of P5A-2F11_3B,Epididymis luminal protein 214,Epididymis luminal protein 214: DFH
IG c168_light_IGKV4-1_IGKJ4,Immunoglobulin kappa constant: EGI - SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AB
BC
CD
HF
IH
JE
KG
MI
N
- Coordinates
- PDB Format
- Method
- ELECTRON MICROSCOPY
- Oligo State
- hetero-3-3-3-mer
- Ligands
- 22 x NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- 3 x NAG- NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 27 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)(Non-functional Binders)
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Yan, R. et al., Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodies. Cell Res. (2021)
- Release Date
- 2021-03-10
- Peptides
- Spike glycoprotein: ABC
Immunoglobulin heavy variable 1-8,Immunoglobulin heavy variable 1-8,chain H of P5A-2F11_3B,Epididymis luminal protein 214,Epididymis luminal protein 214: DFH
IG c168_light_IGKV4-1_IGKJ4,Immunoglobulin kappa constant: EGI - SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AB
BC
CD
HF
IH
JE
KG
MI
N